| VRSK |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.97 vs. cons $1.94 |
MEDIUM |
| VRSK |
Report |
Revenue |
BEAT |
pred ~$813M vs. cons $804M |
MEDIUM |
| VRSK |
Report |
Organic constant-currency revenue growth |
IN-LINE |
pred ~5.4% vs. cons 5.5% |
LOW |
| VRSK |
Guide |
FY26 revenue guidance midpoint |
LOWER |
guide ~$3.215B vs. cons $3.220B (FY26) |
MEDIUM |
| VRSK |
Guide |
FY26 adjusted EBITDA guidance midpoint |
UNCHANGED |
guide ~$1.810B vs. cons $1.810B (FY26) |
MEDIUM |
| VRSK |
Guide |
FY26 adjusted diluted EPS guidance midpoint |
LOWER |
guide ~$7.60 vs. cons $7.64 (FY26) |
MEDIUM |
| VRSK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| VRSK |
Return |
5-day cumulative residual |
-5.0% (FOLLOW-THROUGH) |
A modest ~$1.97 vs. $1.94 EPS beat and ~$813M vs. $804M revenue beat are unlikely to offset unchanged FY26 revenue of ~$3.215B versus ~$3.220B consensus and EPS of ~$7.60 versus ~$7.64 consensus; the resulting out-period estimate-reset risk should extend the initial negative residual move. |
MEDIUM |